AlphAIAlphAI — Financial news for AI agents
simplywall.stAUG 211 min read$LILA

Liberty Latin America (LILA) Could Be 26% Undervalued On Malone Share Buying

Liberty Latin America (LILA) Director Emeritus John C. Malone increased his indirect stake by 50,696 Class A shares, bringing his total to about 4.0 million shares. The stock trades at $8.17, with a 1-month return of 10.11% but a 5-year return of -43.26%. Analysts suggest the company could be 26% undervalued at $11.07 per share, citing operational improvements and strategic restructuring. However, the valuation depends on reducing debt and managing refinancing pressures.

Original reporting
simplywall.st
Published Aug 21, 2026, 7:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liberty Latin America (LILA) Could Be 26% Undervalued On Malone Share Buying — source image
Source · simplywall.st
Decision brief

The 30-second read

$LILANeutralLow
01

Why it matters

The article provides a modest insider‑buy signal without new corporate actions.

02

Market read

Minor insider activity; unlikely to affect broader market.

03

What to watch

Potential upcoming restructuring of Liberty Puerto Rico could change fundamentals.

Relevance 4/10Novelty 3/10Timing: recently reported

Background

Liberty Latin America is a telecom operator in Latin America; recent share price has risen 10% month‑to‑date but down 43% over five years.

Company-level read

Ticker impact

$LILANeutralMedium confidence
Context

John C. Malone added 50,696 Class A shares, raising his stake to about 1% as the stock trades around $8.17.

Expected impact

minimal short‑term effect

Evidence & confidence

The purchase size is modest relative to float and recent price move, so unlikely to drive price.

Market effects

Sector

Limited; reflects insider sentiment in telecom sector.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider buying may be routine and not indicative of future upside.

Key entities

  • individual
    John C. Malone

    Director Emeritus of Liberty Latin America, insider buyer.

Read at source← All news

Related articles

AUG 13
$LILAMed

Liberty Latin America (LILA) Q2 2026 Earnings Call Transcript

Liberty Latin America (LILA) reported Q2 2026 revenue of $1.1 billion (1% growth), adjusted OIBDA of $436 million (+3% rebased), and adjusted free cash flow of $83 million. Total debt was $8.5 billion, net leverage 4.6x, and cash $747 million. The company also discussed repurchases, a $500 million preferred distribution, and a 10-year Amdocs IT and AI deal.

fool.com6 min
AUG 5
$LILAMed

Liberty Latin America Reports Q2 2026 Results

Liberty Latin America Ltd. (LILA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liberty Latin America Reports Q2 2026 Results Gained 45,000 postpaid and broadband net adds in Q2 Operating Income & Adjusted OIBDA YoY growth Significant expansion in cash flow from operations and Adjusted FCF Completed preferred stock distribution; declared quarter

SEC EDGAR 8-K6 min
OCT 15
$ABBVMed

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.

finance.yahoo.com2 min
OCT 15
$PRAXMed

PRAX Initiated Coverage by UBS -- Price Target Announced at $706

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

gurufocus.com2 min
OCT 15
$REGNMed

REGN Upgraded by UBS -- Price Target Raised to $978

UBS upgraded Regeneron Pharmaceuticals (REGN) to 'Buy' with a $978 price target, up 48.18% from $660. GuruFocus values REGN at $925.48, suggesting it's 14.0% undervalued. The company has a GF Score of 87/100, strong financials, and a market cap of $81.99B. Analysts cite growth potential and resilience in its products, like Eylea and Dupixent.

gurufocus.com1 min